Thomas E. Dunn is a partner in Cravath’s Corporate Department. His diverse corporate practice encompasses mergers and acquisitions, private equity, joint ventures, restructurings, corporate governance and securities‑related matters.
Mr. Dunn’s clients have included Ashland, Pentair, Chemed, Aptuit, Associated Partners, Genpact, BAE Systems, Bristol‑Myers Squibb, J.Crew, Barnes & Noble, Gerber Scientific, Terra Industries, Jones Apparel Group, Ripplewood Holdings, RHJ International, Alcoa and Perry Capital.
Mr. Dunn’s recent assignments include representing Genpact in connection with an approximately $1 billion investment by Bain Capital; Pentair in its $10 billion “reverse Morris Trust” combination with Tyco Flow Control; Aptuit in the sale of its CTS business to Catalent for $407 million; Ashland in its $3.2 billion acquisition of International Specialty Products; Gerber Scientific in its $281 million leveraged buyout by Vector Capital; The Special Committee of the J.Crew Board of Directors in its $3 billion leveraged buyout by TPG and Leonard Green; Barnes & Noble in its successful proxy contest with Ron Burkle and Yucaipa; Terra Industries in connection with its $4.7 billion sale to CF Industries; Jones Apparel Group in its acquisition of Stuart Weitzman; Bristol‑Myers Squibb in its $2.4 billion acquisition of Medarex; Chemed in its proxy fight with MMI Investments; RHJ International and its portfolio company, Asahi Tec, in connection with the restructuring of Metaldyne Corporation; Bristol‑Myers Squibb in its $4.7 billion bid for ImClone; Bristol‑Myers Squibb in its $4.1 billion sale of ConvaTec; and Alcoa in the $2.7 billion sale of its packaging and consumer business to Rank Group Limited.
Among other transactions, Mr. Dunn also represented Ripplewood in its $352 million sale of Supresta to Israel Chemicals Ltd. and in its joint venture investment in AirCell; Perry Capital, LLC, Marathon Asset Management, D.E. Shaw & Co. and Tennenbaum Capital Partners in connection with their formation, together with Bear Stearns Merchant Banking, of Doral Holdings, L.P., which in turn acquired 90% of Doral Financial Corporation for $610 million; Asahi Tec in its acquisition of Metaldyne; WPS Resources in its $1.6 billion acquisition of Peoples Energy Corporation; RHJ International in its reorganization from Ripplewood Holdings’ private equity fund in Japan into a public company listed in Belgium; Renal Care Group in its $4 billion acquisition by Fresenius Medical Care AG; Bristol‑Myers Squibb in its $660 million sale of its consumer medicines business to Novartis AG, its $385 million sale of its adult nutritional business to Novartis AG, its $7.8 billion acquisition of DuPont Pharmaceuticals, its sale of Matrix Essentials to L’Oreal and its spin‑off of Zimmer; Ripplewood Holdings in its €600 million acquisition of Honsel International Technologies from the Carlyle Group and its €230 million acquisition of Akzo Nobel NV’s phosphorous chemical business; Roto Rooter in connection with its $410 million acquisition of Vitas Healthcare; and OfficeMax in its $1.2 billion acquisition by Boise Cascade Corporation.
Mr. Dunn is a member of the Board of Directors of MFY Legal Services, the Board of Trustees of Greenwich Academy and the Board of Visitors of Western Reserve Academy.
Mr. Dunn was raised in Erie, Pennsylvania. He received a B.A. from the College of William & Mary in 1987 and a J.D. with high honors from Duke University School of Law in 1992, where he was Senior Editor of Law and Contemporary Problems and was elected to the Order of the Coif. Mr. Dunn joined Cravath in 1992, spent two years as an associate in Cravath’s London office and became a partner in 2000.
Mr. Dunn may be reached by phone at 212‑474‑1108 or by email at firstname.lastname@example.org.